DXR
Price
$10.00
Change
-$0.00 (-0.00%)
Updated
Aug 21 closing price
Capitalization
58.38M
One day until earnings call
Intraday BUY SELL Signals
SHC
Price
$19.57
Change
+$0.35 (+1.82%)
Updated
Aug 21 closing price
Capitalization
5.58B
79 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DXR vs SHC

DXR vs SHC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DXR vs. SHC commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXR is a Hold and SHC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (DXR: $10.00 vs. SHC: $19.57)
Brand notoriety: DXR and SHC are both not notable
DXR represents the Pharmaceuticals: Other, while SHC is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: DXR: 101% vs. SHC: 73%
Market capitalization -- DXR: $58.38M vs. SHC: $5.58B
DXR [@Pharmaceuticals: Other] is valued at $58.38M. SHC’s [@Medical Specialties] market capitalization is $5.58B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $133.83B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.59B. The average market capitalization across the [@Medical Specialties] industry is $18.77B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DXR’s FA Score shows that 0 FA rating(s) are green whileSHC’s FA Score has 0 green FA rating(s).

  • DXR’s FA Score: 0 green, 5 red.
  • SHC’s FA Score: 0 green, 5 red.
According to our system of comparison, SHC is a better buy in the long-term than DXR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DXR’s TA Score shows that 3 TA indicator(s) are bullish while SHC’s TA Score has 5 bullish TA indicator(s).

  • DXR’s TA Score: 3 bullish, 6 bearish.
  • SHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SHC is a better buy in the short-term than DXR.

Price Growth

DXR (@Pharmaceuticals: Other) experienced а -1.09% price change this week, while SHC (@Medical Specialties) price change was +3.60% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.08%. For the same industry, the average monthly price growth was +10.50%, and the average quarterly price growth was +5.94%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +5.67%. For the same industry, the average monthly price growth was +14.62%, and the average quarterly price growth was +35.84%.

Reported Earning Dates

DXR is expected to report earnings on Aug 24, 2026.

SHC is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-0.08% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (+5.67% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SHC($5.59B) has a higher market cap than DXR($58.4M). SHC has higher P/E ratio than DXR: SHC (34.33) vs DXR (6.10). SHC YTD gains are higher at: 10.941 vs. DXR (-32.203). DXR has less debt than SHC: DXR (263K) vs SHC (2.27B). SHC has higher revenues than DXR: SHC (1.19B) vs DXR (10.3M).
DXRSHCDXR / SHC
Capitalization58.4M5.59B1%
EBITDAN/A481M-
Gain YTD-32.20310.941-294%
P/E Ratio6.1034.3318%
Revenue10.3M1.19B1%
Total CashN/A314M-
Total Debt263K2.27B0%
FUNDAMENTALS RATINGS
DXR: Fundamental Ratings
DXR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
96
SMR RATING
1..100
42
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DXRSHC
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
73%
Momentum
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
65%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
61%
Advances
ODDS (%)
Bullish Trend 13 days ago
67%
Bullish Trend 3 days ago
68%
Declines
ODDS (%)
Bearish Trend 11 days ago
73%
Bearish Trend 6 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
DXR
Daily Signal:
Gain/Loss:
SHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWSSX18.800.17
+0.91%
Invesco Global Core Equity R6
RYSGX69.260.53
+0.77%
Rydex S&P SmallCap 600 Pure Growth A
WLGRX34.300.15
+0.44%
Nomura Large Cap Growth R
DIFHX12.930.02
+0.15%
MFS Diversified Income R6
ICPAX9.11-0.02
-0.22%
Integrity Mid-North American Resources A

DXR and

Correlation & Price change

A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXR
1D Price
Change %
DXR100%
N/A
IART - DXR
33%
Poorly correlated
+0.90%
BWAY - DXR
27%
Poorly correlated
-1.54%
AVTR - DXR
23%
Poorly correlated
+1.47%
COO - DXR
20%
Poorly correlated
+0.08%
SHC - DXR
20%
Poorly correlated
+1.82%
More

SHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, SHC has been loosely correlated with RVTY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SHC jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SHC
1D Price
Change %
SHC100%
+1.82%
RVTY - SHC
53%
Loosely correlated
+0.50%
CRL - SHC
52%
Loosely correlated
+1.28%
MTD - SHC
49%
Loosely correlated
+0.14%
TMO - SHC
48%
Loosely correlated
+0.27%
DHR - SHC
47%
Loosely correlated
+1.36%
More